{
    "root": "3090c1e0-c37b-d376-e063-6294a90a1cab",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tofidence",
    "value": "20250317",
    "ingredients": [
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "ARGININE HYDROCHLORIDE",
            "code": "F7LTH1E20Y"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "TOCILIZUMAB",
            "code": "I031V2H011"
        }
    ],
    "indications": "tofidence\u2122 ( tocilizumab-bavi ) interleukin-6 ( il-6 ) receptor antagonist indicated treatment : rheumatoid arthritis ( rheumatoid arthritis ) ( 1.1 ) adult patients moderately severely active rheumatoid arthritis inadequate response one disease-modifying anti-rheumatic drugs ( dmards ) . giant cell arteritis ( gca ) ( 1.2 ) adult patients giant cell arteritis . polyarticular juvenile idiopathic arthritis ( pjia ) ( 1.3 ) patients 2 years age older active polyarticular juvenile idiopathic arthritis . systemic juvenile idiopathic arthritis ( sjia ) ( 1.4 ) patients 2 years age older active systemic juvenile idiopathic arthritis . coronavirus disease 2019 ( covid-19 ) ( 1.5 ) hospitalized adult patients coronavirus disease 2019 ( covid-19 ) receiving systemic corticosteroids require supplemental oxygen , non-invasive invasive mechanical ventilation , extracorporeal membrane oxygenation ( ecmo ) .",
    "contraindications": "rheumatoid arthritis , pjia sjia , tofidence may used alone combination methotrexate ; rheumatoid arthritis , non-biologic dmards may used . ( 2 ) general dosing information ( 2.1 ) rheumatoid arthritis , gca , pjia sjia - recommended tofidence initiated patients absolute neutrophil count ( anc ) 2000 per mm 3 , platelet count 100,000 per mm 3 , alt ast 1.5 times upper limit normal ( uln ) . ( 5.3 , 5.4 ) covid-19 - recommended tofidence initiated patients absolute neutrophil count ( anc ) 1000 per mm3 , platelet count 50,000 mm3 , alt ast 10 times uln ( 5.3 , 5.4 ) . rheumatoid arthritis covid-19 patients , tofidence doses exceeding 800 mg per infusion recommended . ( 2.2 , 12.3 ) gca patients , tofidence doses exceeding 600 mg per infusion recommended . ( 2.3 , 12.3 ) rheumatoid arthritis ( 2.2 ) recommended adult intravenous : used combination non-biologic dmards monotherapy recommended starting dose 4 mg per kg every 4 weeks followed increase 8 mg per kg every 4 weeks based response . giant cell arteritis ( 2.3 ) recommended adult intravenous : recommended dose 6 mg per kg every 4 weeks combination tapering course glucocorticoids . tofidence used alone following discontinuation glucocorticoids . polyarticular juvenile idiopathic arthritis ( 2.4 ) recommended intravenous pjia every 4 weeks patients less 30 kg weight 10 mg per kg patients 30 kg weight 8 mg per kg systemic juvenile idiopathic arthritis ( 2.5 ) recommended intravenous sjia every 2 weeks patients less 30 kg weight 12 mg per kg patients 30 kg weight 8 mg per kg coronavirus disease 2019 ( 2.6 ) recommended tofidence adult patients covid-19 8 mg per kg administered 60-minute intravenous infusion . intravenous formulation ( 2.7 ) patients rheumatoid arthritis , gca , covid-19 , pjia , sjia patients 30 kg , dilute 100 ml 0.9 % sodium chloride injection , usp intravenous infusion using aseptic technique . pjia sjia patients less 30 kg , dilute 50 ml 0.9 % sodium chloride injection , usp intravenous infusion using aseptic technique . administer single intravenous drip infusion 1 hour ; administer bolus push . dose modifications ( 2.8 ) recommended management certain dose-related laboratory changes including elevated liver enzymes , neutropenia , thrombocytopenia .",
    "warningsAndPrecautions": "tofidence ( tocilizumab-bavi ) injection preservative-free , sterile , clear opalescent , colorless light yellow solution . tofidence supplied 80 mg/4 ml ( ndc 64406-024-01 ) , 200 mg/10 ml ( ndc 64406-022-01 ) , 400 mg/20 ml ( ndc 64406-023-01 ) individually packaged 20 mg/ml single-dose vials dilution prior intravenous infusion .",
    "adverseReactions": "tofidence contraindicated patients known hypersensitivity tocilizumab products [ ( 5.6 ) ] .",
    "indications_original": "TOFIDENCE\u2122 (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Coronavirus Disease 2019 (COVID-19) ( 1.5 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).",
    "contraindications_original": "For RA, pJIA and sJIA, TOFIDENCE may be used alone or in combination with methotrexate; and in RA, other non-biologic DMARDs may be used. ( 2 ) General Administration and Dosing Information ( 2.1 ) RA, GCA, PJIA and SJIA - It is recommended that TOFIDENCE not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm 3 , platelet count below 100,000 per mm 3 , or ALT or AST above 1.5 times the upper limit of normal (ULN). ( 5.3 , 5.4 ) COVID-19 - It is recommended that TOFIDENCE not be initiated in patients with an absolute neutrophil count (ANC) below 1000 per mm3 , platelet count below 50,000 mm3 , or ALT or AST above 10 times ULN ( 5.3 , 5.4 ). In RA or COVID-19 patients, TOFIDENCE doses exceeding 800 mg per infusion are not recommended. ( 2.2 , 12.3 ) In GCA patients, TOFIDENCE doses exceeding 600 mg per infusion are not recommended. ( 2.3 , 12.3 ) Rheumatoid Arthritis ( 2.2 ) Recommended Adult Intravenous Dosage: When used in combination with non-biologic DMARDs or as monotherapy the recommended starting dose is 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response. Giant Cell Arteritis ( 2.3 ) Recommended Adult Intravenous Dosage: The recommended dose is 6 mg per kg every 4 weeks in combination with a tapering course of glucocorticoids. TOFIDENCE can be used alone following discontinuation of glucocorticoids. Polyarticular Juvenile Idiopathic Arthritis ( 2.4 ) Recommended Intravenous PJIA Dosage Every 4 Weeks Patients less than 30 kg weight 10 mg per kg Patients at or above 30 kg weight 8 mg per kg Systemic Juvenile Idiopathic Arthritis ( 2.5 ) Recommended Intravenous SJIA Dosage Every 2 Weeks Patients less than 30 kg weight 12 mg per kg Patients at or above 30 kg weight 8 mg per kg Coronavirus Disease 2019 ( 2.6 ) The recommended dosage of TOFIDENCE for adult patients with COVID-19 is 8 mg per kg administered by a 60-minute intravenous infusion. Administration of Intravenous Formulation ( 2.7 ) For patients with RA, GCA, COVID-19, PJIA, and SJIA patients at or above 30 kg, dilute to 100 mL in 0.9% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique. For PJIA and SJIA patients less than 30 kg, dilute to 50 mL in 0.9% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique. Administer as a single intravenous drip infusion over 1 hour; do not administer as bolus or push. Dose Modifications ( 2.8 ) Recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia.",
    "warningsAndPrecautions_original": "TOFIDENCE (tocilizumab-bavi) injection is a preservative-free, sterile, clear to opalescent, colorless to light yellow solution. TOFIDENCE is supplied as 80 mg/4 mL (NDC 64406-024-01), 200 mg/10 mL (NDC 64406-022-01), and 400 mg/20 mL (NDC 64406-023-01) individually packaged 20 mg/mL single-dose vials for further dilution prior to intravenous infusion.",
    "adverseReactions_original": "TOFIDENCE is contraindicated in patients with known hypersensitivity to tocilizumab products\n \n  [see\n  \n   Warnings and Precautions (5.6)]."
}